Phase 4
Completed N=44
Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study
Drug Induced Hyperglycemia · Secondary Hyperlipidemia
Source: ClinicalTrials.gov NCT01409434 ↗
Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Oct 2014
Primary outcomePrimary: Fasting Glucose (mg/dL) — 94 mg/dL
Summary
This is a research study of the long term effects on blood sugar and cholesterol of blood pressure lowering medications. People are invited to participate in this research study if they participated in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR 1, NCT00246519 or PEAR 2, NCT01203852) study and are still taking a thiazide diuretic. In PEAR, the effects on blood pressure, blood sugar, and cholesterol of the high blood pressure drugs hydrochlorothiazide and atenolol over an 18 week period were evaluated. This PEAR follow-up study will determine the effects of thiazide diuretics on blood sugar and cholesterol, but in the period since the PEAR trial. The study hypothesis is that long term exposure to thiazide diuretics results in larger increases in blood sugar and cholesterol levels than short term exposure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fasting Glucose (mg/dL) |
94 | — |
| SECONDARY Oral Glucose Tolerance Test (mg/dl h) |
273 | — |
| SECONDARY Triglycerides (mg/dL) |
157 | — |
| SECONDARY Low Density Lipoprotein (mg/dL) |
117 | — |
| SECONDARY High Density Lipoprotein (mg/dL) |
52 | — |
Eligibility Criteria
Inclusion Criteria
- previously enrolled in PEAR study
- completed last PEAR study visit greater than 6 months prior
- receive thiazide diuretic continuously since PEAR enrollment
Exclusion Criteria
- pregnancy
Data sourced from ClinicalTrials.gov (NCT01409434). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.